Key clinical point: The anti–programmed death-1 antibody toripalimab, combined with the vascular endothelial growth factor inhibitor axitinib, produced responses in patients with metastatic mucosal melanoma.

Major finding: As of May 2, 2020, the overall response rate was 48.5%, which included 1 complete response and 15 partial responses.

Study details: A phase 1b study of 33 subjects.

Disclosures: The study was funded by the maker of toripalimab, Shanghai Junshi Bioscience. Investigators disclosed relationships, including employment, with Shanghai Junshi Bioscience and Pfizer, maker of axitinib.